Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00381628 · ClinicalTrials.gov registry record
Nasal Epithelial Cells/Blood Lymphocyte Markers for Cystic Fibrosis (CF)/CF Pulmonary Exacerbations
A clinical trial, sponsored by University Hospitals Cleveland Medical Center.
- Completed
- Registry status
- 59
- Enrollment target
NCT00381628 is a clinical trial that has completed, run by University Hospitals Cleveland Medical Center. The registered enrollment target is 59 participants.
The verdict
NCT00381628 has completed, sponsored by University Hospitals Cleveland Medical Center.
- COMPLETED
- Registry status
- 59 participants
- Enrollment target
Study Summary
Study Hypothesis: We hypothesize that cellular markers from nasal epithelial cells and blood lymphocytes can serve as potential biomarkers reflect the underlying inflammatory state of the lung and will be helpful in determining the presence of a CF pulmonary exacerbation and its overall severity.
Interventions
- PROCEDURE epithelial cells and blood lymphocyte extraction
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2006-09 |
| Est. Completion | 2011-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00381628
The ClinicalTrials.gov registry entry for NCT00381628 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University Hospitals Cleveland Medical Center, which has 230 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which epithelial cells and blood lymphocyte extraction is the first listed.
NCT00381628 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00381628 about?
NCT00381628 is a clinical study titled "Nasal Epithelial Cells/Blood Lymphocyte Markers for Cystic Fibrosis (CF)/CF Pulmonary Exacerbations". Study Hypothesis: We hypothesize that cellular markers from nasal epithelial cells and blood lymphocytes can serve as potential biomarkers reflect the underlying inflammatory state of the lung and will be helpful in determining the presence of a CF pulmonary exacerbation and its overall severity.
What is the current status of trial NCT00381628?
This trial is currently completed. The enrollment target is 59 participants. The study started on 2006-09. Estimated completion is 2011-09.
What interventions are being tested in trial NCT00381628?
The interventions under investigation include: epithelial cells and blood lymphocyte extraction (PROCEDURE).
Who is sponsoring clinical trial NCT00381628?
This trial is sponsored by University Hospitals Cleveland Medical Center, which has 230 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.